Plain-English translation of NCT06591429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study is investigating a type of ongoing, low-level inflammation in multiple sclerosis that may not be stopped by current medications. Researchers will use advanced imaging scans and analyze spinal fluid from people with MS who are starting a new, high-efficacy treatment to identify which parts of this hidden inflammation resist treatment and may be driving disability over time.
Even though today's best MS medications dramatically reduce relapses and new brain lesions, most patients still experience gradual worsening and disability. Researchers believe there is a type of smoldering—or slowly burning—inflammation that current treatments don't fully address, and identifying it could lead to new therapies to stop this progression.
You likely qualify if…
You likely don't qualify if…
You will undergo advanced imaging scans (PET and MRI) and have a spinal tap to collect cerebrospinal fluid for detailed analysis. These procedures will likely occur around the time you start your new MS medication. The study involves 25 adults with MS being treated at Washington University in St. Louis, and participants are recruited through their treating neurologist.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Sponsor
Washington University School of Medicine
Enrollment target
~25 participants
Started
June 2024
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthew Brier, MD, PhD
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.